Please wait while the formulary information is being retrieved.
LYRICA CR (pregabalin)
- diabetic complication causing injury to some body nerves
- nerve pain after herpes
165 mg tablet,extended release
- 1 tablet (165 mg) by oral route once daily at the same time eachday
330 mg tablet,extended release
- 1 tablet (330 mg) by oral route once daily at the same time eachday
82.5 mg tablet,extended release
- 1 tablet (82.5 mg) by oral route once daily at the same time each day
Default screening record
- 2 tablets (165 mg) by oral route once daily at the same time each day
- 1 tablet (165 mg) by oral route once daily at the same time eachday
- 3 tablets (247.5 mg) by oral route once daily at the same time each day
- 2 tablets (330 mg) by oral route once daily at the same time each day
- 1 tablet (330 mg) by oral route once daily at the same time eachday
- 3 tablets (495 mg) by oral route once daily at the same time each day
- 2 tablets (660 mg) by oral route once daily at the same time each day
- 1 tablet (82.5 mg) by oral route once daily at the same time each day
- None
Contraindicated
- sodium oxybate
- Xyrem
Severe
Moderate
- Actoplus Met
- Actoplus Met Xr
- Actos
- alogliptin-pioglitazone
- Astramorph-pf
- Avinza
- Depodur (pf)
- Duetact
- Duramorph (pf)
- Kadian
- morphine
- morphine (PF)
- morphine concentrate
- morphine liposomal (PF)
- Ms Contin
- Oseni
- pioglitazone
- pioglitazone-glimepiride
- pioglitazone-metformin
- Rhabdomyolysis
Contraindicated
- Acute decompensated heart failure
- Angioedema
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Chronic obstructive pulmonary disease
- Myopathy with CK elevation
- Respiratory depression
- Suicidal ideation
Severe
Moderate
- Atrioventricular block
- Chronic heart failure
- Depression
- Kidney disease with likely reduction in GFR
- Peripheral edema
- Reduced visual acuity
- Weight gain
LYRICA CR (pregabalin)
- diabetic complication causing injury to some body nerves
- nerve pain after herpes
- Ataxia
- Blurred vision
- Concentration difficulty
- Disturbance in thinking
- Dizziness
- Drowsy
- Fatigue
- Peripheral edema
- Weight gain
- Xerostomia
More Frequent
Severe
Less Severe
- Facial edema
- Infection
- Thrombocytopenic disorder
- Accidental injury
- Acute abdominal pain
- Acute confusion
- Arthralgia
- Back pain
- Constipation
- Euphoria
- Gastroenteritis
- General weakness
- Headache disorder
- Hypoesthesia
- Increased appetite
- Memory impairment
- Muscle fasciculation
- Muscle spasm
- Orgasm disorder
- Pruritus of skin
- Sinusitis
- Vertigo
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Angioedema
- Behavioral disorders
- Blistering skin
- Bullous pemphigoid
- Diplopia
- Drug dependence
- Dysarthria
- Dyskinesia
- Heart failure
- Hypoglycemic disorder
- Kidney stone
- Prolonged PR interval
- Respiratory depression
- Suicidal ideation
- Tinnitus
- Urticaria
- Wheezing
Less Severe
- Abdominal distension
- Acute bacterial otitis media
- Amenorrhea
- Bronchitis
- Chest pain
- Conjunctivitis
- Cramps in legs
- Depersonalization
- Diarrhea
- Dysmenorrhea
- Dyspareunia
- Dyspnea
- Dysuria
- Ecchymosis
- Edema
- Erectile dysfunction
- Erythema
- Fever
- Flatulence
- Flu-like symptoms
- Gait abnormality
- Gynecomastia
- Hematuria
- Hypertonia
- Increased urinary frequency
- Libido changes
- Muscle weakness
- Myalgia
- Nail disorders
- Nausea
- Nervousness
- Nystagmus
- Skin rash
- Stupor
- Symptoms of anxiety
- Tremor
- Urinary incontinence
- Visual changes
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Pregabalin
Safety and efficacy not established for age < 1 month.
- 1 Day – 29 Days
- Safety and efficacy not established for age < 1 month.
Pregabalin
- Severity Level:
2
- Additional Notes: Insuff human data; animal data sug dev tox at >10 times mrhd
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Pregabalin
Limited data suggest excretion in very low amounts
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data suggest excretion in very low amounts |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Pregabalin
Renal-Adjust dose for CrCl < 60 mL/min. Neuro/Psych-Can cause ataxia, impaired psychomotor function, syncope, and additional falls. Avoid concomitant opioids except when transitioning therapy. Pulmonary-Elderly may be at higher risk for respiratory depression. Risk is highest in elderly with pre-existing chronic pulmonary disease or with concomitant use of opioids.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | Y | Y | N |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- None
| Diabetic peripheral neuropathy | |
| E08.40 | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified |
| E08.42 | Diabetes mellitus due to underlying condition with diabetic polyneuropathy |
| E09.40 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified |
| E09.42 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy |
| E10.40 | Type 1 diabetes mellitus with diabetic neuropathy, unspecified |
| E10.42 | Type 1 diabetes mellitus with diabetic polyneuropathy |
| E11.40 | Type 2 diabetes mellitus with diabetic neuropathy, unspecified |
| E11.42 | Type 2 diabetes mellitus with diabetic polyneuropathy |
| E13.40 | Other specified diabetes mellitus with diabetic neuropathy, unspecified |
| E13.42 | Other specified diabetes mellitus with diabetic polyneuropathy |
| Postherpetic neuralgia | |
| B02.22 | Postherpetic trigeminal neuralgia |
| B02.23 | Postherpetic polyneuropathy |
| 0-9 | A-Z |
|---|---|
| B02.22 | Postherpetic trigeminal neuralgia |
| B02.23 | Postherpetic polyneuropathy |
| E08.40 | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified |
| E08.42 | Diabetes mellitus due to underlying condition with diabetic polyneuropathy |
| E09.40 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified |
| E09.42 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy |
| E10.40 | Type 1 diabetes mellitus with diabetic neuropathy, unspecified |
| E10.42 | Type 1 diabetes mellitus with diabetic polyneuropathy |
| E11.40 | Type 2 diabetes mellitus with diabetic neuropathy, unspecified |
| E11.42 | Type 2 diabetes mellitus with diabetic polyneuropathy |
| E13.40 | Other specified diabetes mellitus with diabetic neuropathy, unspecified |
| E13.42 | Other specified diabetes mellitus with diabetic polyneuropathy |
Formulary Reference Tool